Emerging data suggest Retatrutide , a dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , appears to offer a significant advancement for weight management . Initial patient tests have demonstrated impressive reductions in visceral fat , potentially outperforming existing weight-loss therapies . Nevertheless , additi